When Hormone Therapy CAN Prevent Cancer - What and Why They Aren't Telling You; C.W Randolph, Jr., M.D. Speaks Out

Share Article

A study just released indicates that women who took synthetic hormone drugs (such as the popular Premarin and Prempro) for more than five years, today continue to have an elevated risk of developing cancer years after they stopped taking the drugs.

The Journal of American Medical Association has just released a study that indicates women who took synthetic hormone drugs for more than five years continue to have an elevated risk of developing cancer years after they stopped taking the drugs.

C.W. Randolph, Jr., M.D., nationally recognized expert in the field bio-identical hormone replacement therapies, said today "The publication of this study's finding is so important. I have been so concerned that even after the 2002 results of the Women's Health Initiative Study (WHI) linking synthetic hormone usage to an increased risk of invasive breast cancer, heart attack, stroke and Alzheimer's disease - the pharmaceutical industry continued to aggressively market these same drugs to both physicians and women as safe and effective options. Now, with this data, it will be harder for those manufacturing synthetic hormones for a profit to submerge the truth and harm the health of innocent women."

"The medical evidence that synthetic hormones are dangerous has been out there for decades," says Dr. Randolph. "In her book The Greatest Experiment Ever Performed On Women, Exploding the Estrogen Myth Barbara Seamen documents how in April 1941, just as the FDA was examining applications from Eli Lilly, Squibb and several other pharmaceutical companies to approve synthetic estrogen products for the treatment of menopause, Edgar Allen, M.D., chair of the anatomy department at Yale Medical School, published an article in the journal Cancer Research linking these same synthetic estrogens to cancer. Unfortunately, because these drugs promised to be such market blockbusters, the FDA ignored their potential carcinogenic properties. As always, when marketing gets ahead of science, people suffer. As a result, for more than sixty years, women put on synthetic hormones have unnecessarily been put in a higher risk category for breast cancer development as well as other potentially lethal health risks."

"What is just as egregious as how the data about the link between synthetic hormone usage and cancer has been suppressed is the fact that the media and the FDA are not informing physicians and women-at-large that bio-identical hormones are a safe and effective alternative for treating hormone imbalances and menopausal symptoms. There is - and has been for decades - clinical studies and medical data supporting the safety and efficacy of bio-identical hormone therapies but, unfortunately, most people remain unaware. There is actually a most exciting French cohort study published in the Nov 18, 2004 issue of the International Journal of Cancer that indicated that bio-identical progesterone evidenced a cancer-protective action within the female body."

When asked why bio-identical hormone therapies are not more generally accepted, Dr. Randolph has a simple answer: "Money and ignorance. Think about it. Bio-identical hormones have the exact same molecular structure as the hormones produced by the ovaries or testes so, therefore, they can't be patented. Synthetic hormones are chemically altered hormones (like Provera, medroxyprogesterpone, or Premarin, conjugated estrified equine estrogens) do not exactly match the hormones produced by the body. That is why they can be patented. Unfortunately for thousands of women, the fact that they don't match is also why they trigger lethal side effects such as this now documented long-term increased cancer risk."

"Most doctors remain unaware about the safety and efficacy of bio-identical hormone therapies because, unlike billion dollar pharmaceutical companies, the medical research and academic institutes publishing research in this area do not have large budgets for mass marketing or large sales forces to deliver these studies to a doctor's office along with lunch for his/her staff."

Dr. Randolph concludes with this question: "More investigation in this country regarding the safety, efficacy and cancer-protective properties of bio-identical hormones is absolutely needed. My question is why hasn't the National Institute of Health already funded it? Could it be that the financial power of the pharmaceutical giants continuing to promote synthetic hormone drugs continues to wield influence to submerge the truth in an effort to protect their waning profits?"

For the record: When the results of WHI were originally released in 2002 over fifty percent of the 8 million women on synthetic hormones stopped cold turkey. Wyeth, the manufacturer of the then popular Premarin and Prempro, financial reports (which are available online at http://www.wyeth.com) suggest an ongoing and significant decline in the sales of the Premarin synthetic hormone family of products; e.g. from over $2 billion in 2002 to $880 million in 2004; a 68% decline in sales. Just recently, Wyeth also announced that it will be reducing its field sales force by 10%.

C.W. Randolph, M.D., one of the nation's leading bio-identical hormone doctors, has treated thousands of women and men with hormone imbalances for more than a decade. He is a board certified obstetrician and gynecologist who practiced as a compounding pharmacist before returning to medical school. Dr. Randolph is the co-founder of The Natural Hormone Institute of America and a member of The International Academy of Compounding Pharmacists. He continues to be a frequent speaker for medical and women's organizations across the country and is also the coauthor of the best selling books, From Belly Fat to Belly Flat and From Hormone Hell to Hormone Well.

For media inquiries, contact:Nanette Noffsinger at Burke Hollow Media
(615) 776-4230 or nanette @ burkehollowmedia.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

NANETTE NOFFSINGER
Visit website